BioCentury
ARTICLE | Finance

Polishing up Pearl

Existing VCs back respiratory play Pearl to fund Phase III for COPD

November 19, 2012 8:00 AM UTC

Existing VCs invested $65 million more in Pearl Therapeutics Inc. to support Phase III testing of its lead chronic obstructive pulmonary disease compound, because they think PT003 will offer greater bronchodilation and more reliable dosing than more advanced products.

Last week's series D round brings the total investment in Pearl to $167.5 million. New Leaf Venture Partners, Clarus Ventures and 5AM Ventures participated in the round, which Vatera Healthcare Partners led...